Department of Chemistry
Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease
We report here the first application of Group 9 metal complexes (i.e. iridium(III) and rhodium(III)) as inhibitors of amyloid fibrillogenesis and as luminescent probes for Aβ1-40 peptide. These complexes contained aromatic co-ligands to interact with the hydrophobic residues around the N-terminal domain of the Aβ1-40 peptide, as well as solvato co-ligands to allow coordinative bond formation with histidine residues. We demonstrate that these complexes could inhibit Aβ1-40 peptide aggregation in vitro, with potency superior to previous metal-based inhibitors reported. Furthermore, we have demonstrated the first example of luminescent detection of Aβ1-40 peptides by transition metal complexes. © The Royal Society of Chemistry 2011.
Source Publication Title
Royal Society of Chemistry
Link to Publisher's Edition
Man, B., Chan, H., Leung, C., Chan, D., Bai, L., Jiang, Z., Li, H., & Ma, D. (2011). Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease. Chemical Science, 2 (5), 917-921. https://doi.org/10.1039/C0SC00636J